OmniAb Past Earnings Performance
Past criteria checks 0/6
OmniAb's earnings have been declining at an average annual rate of -30%, while the Life Sciences industry saw earnings growing at 13.6% annually. Revenues have been declining at an average rate of 1.7% per year.
Key information
-30.0%
Earnings growth rate
-118.4%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | -1.7% |
| Return on equity | -21.2% |
| Net Margin | -287.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?
Sep 14
Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 43%?
Jul 15The OmniAb, Inc. (NASDAQ:OABI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade
Mar 26Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)
Feb 28OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price
Jan 15Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares
Nov 11Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts
Aug 13OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially
May 14Revenue & Expenses Breakdown
How OmniAb makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 22 | -62 | 37 | 52 |
| 31 Mar 24 | 21 | -63 | 38 | 53 |
| 31 Dec 23 | 34 | -51 | 38 | 52 |
| 30 Sep 23 | 65 | -30 | 37 | 53 |
| 30 Jun 23 | 66 | -27 | 37 | 50 |
| 31 Mar 23 | 66 | -22 | 33 | 47 |
| 31 Dec 22 | 59 | -22 | 29 | 44 |
| 30 Sep 22 | 39 | -32 | 25 | 40 |
| 30 Jun 22 | 38 | -28 | 19 | 41 |
| 31 Mar 22 | 38 | -25 | 19 | 39 |
| 31 Dec 21 | 35 | -27 | 19 | 37 |
| 30 Sep 21 | 33 | -24 | 16 | 36 |
| 31 Dec 20 | 23 | -18 | 10 | 25 |
| 31 Dec 19 | 18 | -14 | 9 | 13 |
Quality Earnings: OABI is currently unprofitable.
Growing Profit Margin: OABI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OABI is unprofitable, and losses have increased over the past 5 years at a rate of 30% per year.
Accelerating Growth: Unable to compare OABI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OABI is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-11.3%).
Return on Equity
High ROE: OABI has a negative Return on Equity (-21.21%), as it is currently unprofitable.